Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856566 · ClinicalTrials.gov registry record · Early Phase 1
Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations
A Early Phase 1 study of Alcohol Impairment and Marijuana Impairment, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04856566: Completed Early Phase 1 study of Alcohol Impairment and Marijuana Impairment, sponsored by Yale University.
NCT04856566 is a Early Phase 1 study of Alcohol Impairment and Marijuana Impairment that has completed, run by Yale University. The registered enrollment target is 41 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04856566, a Early Phase 1 study of Alcohol Impairment and Marijuana Impairment, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Alcohol and Cannabis (CNB) are two of the most widely used intoxicants. The effects of driving while intoxicated on alcohol are well documented, resulting in numerous drunken driving laws and regulations. As CNB begins to be decriminalized, medical CNB use allowed in multiple U.S. states, and perception of harmfulness falls, CNB use is predicted to rise and it will become increasingly common to publicly encounter persons who recently used the drug. An area of potentially high concern is if ever-greater numbers of CNB users and its legalization will increase the risk of driving while intoxicated from recent CNB use, thereby increasing the risks to public safety. This study aims to examine the combined effects of smoking marijuana and drinking alcohol on simulated driving.
Primary Outcome
The Cogstate 1-back/2-back task assesses working memory, it will be administered prior to dosing and at various time points after dosing.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low Marijuana, Hash, THC, or Grass
- DRUG High Marijuana, Hash, THC, or Grass
- DRUG 0.05 BAC Alcohol
- DRUG 0.08 BAC Alcohol
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2023-08-23 |
| Phase | Early Phase 1 |
What the finished NCT04856566 record still lists
NCT04856566 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (23% lower).
The record links to 2 conditions, with Alcohol Impairment appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT04856566 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04856566 about?
NCT04856566 is a clinical study titled "Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations". Alcohol and Cannabis (CNB) are two of the most widely used intoxicants. The effects of driving while intoxicated on alcohol are well documented, resulting in numerous drunken driving laws and regulations. As CNB begins to be decriminalized, medical CNB use allowed in multiple U.S. states, and percep...
What is the current status of trial NCT04856566?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 41 participants. The study started on 2021-07-28. Estimated completion is 2023-08-23.
What conditions does trial NCT04856566 study?
This clinical trial studies the following conditions: Alcohol Impairment, Marijuana Impairment.
What interventions are being tested in trial NCT04856566?
The interventions under investigation include: Placebo (DRUG), Low Marijuana, Hash, THC, or Grass (DRUG), High Marijuana, Hash, THC, or Grass (DRUG), 0.05 BAC Alcohol (DRUG), 0.08 BAC Alcohol (DRUG).
Who is sponsoring clinical trial NCT04856566?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04856566 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04856566's enrollment target sits among peer trials
41 623rd of 2000 higher than 1,373 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI